COPS5在肿瘤中作用的研究进展

doi:10.3969/j.issn.1673-8640.2019.02.002

摘要/Abstract

摘要：

光发生因子9复合体第5亚基（COPS5）是一种进化保守的多功能蛋白质,在信号转导、细胞增殖、细胞凋亡、细胞周期、基因组不稳定和DNA损伤修复的调控中发挥重要作用。COPS5可通过抑制负调控蛋白和肿瘤抑制因子（P53、P27等）促进肿瘤发生,并与肿瘤进展及放化疗耐受性密切相关;针对COPS5的小分子抑制剂已被初步应用于临床。在不久的将来,COPS5可作为肿瘤治疗的潜在靶点,在肿瘤治疗中发挥更大的作用。文章系统回顾了COPS5在肿瘤发生、发展中的功能以及COPS5相关信号通路的研究进展。

关键词: 光发生因子9复合体第5亚基, 肿瘤, 基因组不稳定, DNA损伤修复

Abstract:

Constitutively photomorphogenic 9 signalosome subunit 5（COPS5） is an evolutionarily conserved and multifunctional protein that plays a role in signal transduction,cell proliferation,cell apoptosis,cell cycle and the regulation of genomic instability and DNA damage response. COPS5 contributes to oncogenesis by functionally inactivating key negative regulatory proteins and tumor suppressors（P53,P27 and so on）,and it is associated with poor prognosis and chemo-radiotherapy tolerance. The small molecule inhibitors for COPS5 have been developed in the preliminary clinical application. Furthermore,COPS5 may serve as a potential therapeutic target and plays a role in tumor treatment. This review focuses on the function of COPS5 in oncogenesis and the research progress of COPS5 signaling pathways.

Key words: Constitutively photomorphogenic 9 signalosome subunit 5, Tumor, Genomic instability, DNA damage response

中图分类号:

R446.1

陈苗苗, 郭林, 卢仁泉. COPS5在肿瘤中作用的研究进展[J]. 检验医学, 2019, 34(2): 98-102.

CHEN Miaomiao, GUO Lin, LU Renquan. Research progress of COPS5 in tumors[J]. Laboratory Medicine, 2019, 34(2): 98-102.

图/表 1

参考文献 36

[1]	CLARET F X,HIBI M,DHUT S,et al.A new group of conserved coactivators that increase the specificity of AP-1 transcription factors[J]. Nature,1996,383(6599):453-457.
[2]	LEE M H,ZHAO R,PHAN L,et al.Roles of COP9 signalosome in cancer[J]. Cell Cycle,2011,10(18):3057-3066.
[3]	GUSMAROLI G,FIGUEROA P,SERINO G,et al.Role of the MPN subunits in COP9 signalosome assembly and activity,and their regulatory interaction with Arabidopsis Cullin3-based E3 ligases[J]. Plant Cell,2007,19(2):564-581.
[4]	CHUNG D,DELLAIRE G.The Role of the COP9 signalosome and neddylation in DNA damage signaling and repair[J]. Biomolecules,2015,5(4):2388-2416.
[5]	PAN L,WANG S,LU T,et al.Protein competition switches the function of COP9 from self-renewal to differentiation[J]. Nature,2014,514(7521):233-236.
[6]	TOMODA K,KUBOTA Y,ARATA Y,et al.The cytoplasmic shuttling and subsequent degradation of p27Kip1 mediated by Jab1/CSN5 and the COP9 signalosome complex[J]. J Biol Chem,2002,277(3):2302-2310.
[7]	SHACKLEFORD T J,CLARET F X.JAB1/CSN5: a new player in cell cycle control and cancer[J]. Cell Div,2010,5:26.
[8]	CECCALDI R,RONDINELLI B,D'ANDREA A D. Repair pathway choices and consequences at the double-strand break[J]. Trends Cell Biol,2016,26(1):52-64.
[9]	PAN Y,ZHANG Q,ATSAVES V,et al.Suppression of Jab1/CSN5 induces radio- and chemo-sensitivity in nasopharyngeal carcinoma through changes to the DNA damage and repair pathways[J]. Oncogene,2013,32(22):2756-2766.
[10]	TIAN L,PENG G,PARANT J M,et al.Essential roles of Jab1 in cell survival,spontaneous DNA damage and DNA repair[J]. Oncogene,2010,29(46):6125-6137.
[11]	HUANG J,YUAN H,LU C,et al.Jab1 mediates protein degradation of the Rad9-Rad1-Hus1 checkpoint complex[J]. J Mol Biol,2007,371(2):514-527.
[12]	CHU I M,HENGST L,SLINGERLAND J M.The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy[J]. Nat Rev Cancer,2008,8(4):253-267.
[13]	SHARMA S S,PLEDGER W J.The non-canonical functions of p27(Kip1) in normal and tumor biology[J]. Cell Cycle,2016,15(9):1189-1201.
[14]	BENCIVENGA D,CALDARELLI I,STAMPONE E,et al.p27Kip1 and human cancers:a reappraisal of a still enigmatic protein[J]. Cancer Lett,2017,403:354-365.
[15]	PAN Y,ZHANG Q,TIAN L,et al.Jab1/CSN5 negatively regulates p27 and plays a role in the pathogenesis of nasopharyngeal carcinoma[J]. Cancer Res,2012,72(7):1890-1900.
[16]	LAUNAY J M,HERVÉ P,PEOC'H K,et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension[J]. Nat Med,2002,8(10):1129-1135.
[17]	ZHANG Q,TIAN L,MANSOURI A,et al.Inducible expression of a degradation-resistant form of p27Kip1 causes growth arrest and apoptosis in breast cancer cells[J]. FEBS Lett,2005,579(18):3932-3940.
[18]	ZHANG H,ZHONG A,SUN J,et al.COPS5 inhibition arrests the proliferation and growth of serous ovarian cancer cells via the elevation of p27 level[J]. Biochem Biophys Res Commun,2017,493(1):85-93.
[19]	JOERGER A C,FERSHT A R.The p53 pathway: origins,inactivation in cancer,and emerging therapeutic approaches[J]. Annu Rev Biochem,2016,85:375-404.
[20]	ZHANG X C,CHEN J,SU C H,et al.Roles for CSN5 in control of p53/MDM2 activities[J]. J Cell Biochem,2008,103(4):1219-1230.
[21]	LEE E W,OH W,SONG H P,et al.Phosphorylation of p53 at threonine 155 is required for Jab1-mediated nuclear export of p53[J]. BMB Rep,2017,50(7):373-378.
[22]	BEMIS L,CHAN D A,FINKIELSTEIN C V,et al.Distinct aerobic and hypoxic mechanisms of HIF-alpha regulation by CSN5[J]. Genes Dev,2004,18(7):739-744.
[23]	BAE M K,AHN M Y,JEONG J W,et al.Jab1 interacts directly with HIF-1alpha and regulates its stability[J]. J Biol Chem,2002,277(1):9-12.
[24]	SUI L,DONG Y,OHNO M,et al.Jab1 expression is associated with inverse expression of p27(kip1) and poor prognosis in epithelial ovarian tumors[J]. Clin Cancer Res,2001,7(12):4130-4135.
[25]	HSU M C,HUANG C C,CHANG H C,et al.Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor gamma ligands in vitro and in vivo[J]. Clin Cancer Res,2008,14(13):4045-4052.
[26]	OSOEGAWA A,YOSHINO I,KOMETANI T,et al.Overexpression of Jun activation domain-binding protein 1 in nonsmall cell lung cancer and its significance in p27 expression and clinical features[J]. Cancer,2006,107(1):154-161.
[27]	KOUVARAKI M A,KORAPATI A L,RASSIDAKIS G Z,et al.Potential role of Jun activation domain-binding protein 1 as a negative regulator of p27kip1 in pancreatic adenocarcinoma[J]. Cancer Res,2006,66(17):8581-8589.
[28]	KOUVARAKI M A,RASSIDAKIS G Z,TIAN L,et al.Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1)[J]. Cancer Res,2003,63(11):2977-2981.
[29]	HOU J,LIU G,YUAN Y,et al.Increased Jab1/COPS5 is associated with therapeutic response and adverse outcome in lung cancer and breast cancer patients[J]. Oncotarget,2017,8(57):97504-97515.
[30]	GAO L,HUANG S,REN W,et al.Jun activation domain-binding protein 1 expression in oral squamous cell carcinomas inversely correlates with the cell cycle inhibitor p27[J]. Med Oncol,2012,29(4):2499-2504.
[31]	SIDDIK Z H.Cisplatin: mode of cytotoxic action and molecular basis of resistance[J]. Oncogene,2003,22(47):7265-7279.
[32]	LU R,HU X,ZHOU J,et al.COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR[J]. Nat Commun,2016,7:12044.
[33]	HSU M C,CHANG H C,HUNG W C.HER-2/neu transcriptionally activates Jab1 expression via the AKT/beta-catenin pathway in breast cancer cells[J]. Endocr Relat Cancer,2007,14(3):655-667.
[34]	LI J,WANG Y,YANG C,et al.Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1[J]. Mol Pharmacol,2009,76(1):81-90.
[35]	PAN Y,WANG M,BU X,et al.Curcumin analogue T83 exhibits potent antitumor activity and induces radiosensitivity through inactivation of Jab1 in nasopharyngeal carcinoma[J]. BMC Cancer,2013,13:323.
[36]	SCHLIERF A,ALTMANN E,QUANCARD J,et al.Targeted inhibition of the COP9 signalosome for treatment of cancer[J]. Nat Commun,2016,7:13166.